Mining the B cell repertoire for broadly neutralizing monoclonal antibodies to HIV-1.
Monoclonal antibodies that effectively neutralize HIV-1 have been widely sought, yet few have been isolated. Now, technological advances in sera evaluation, B cell stimulation, microneutralization, and antibody cloning have allowed Burton and colleagues to identify two broadly neutralizing monoclonal antibodies, PG9 and PG16, which provide insights for HIV vaccine design.
Kwong
Peter D
PD
Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, USA.
Mascola
John R
JR
Nabel
Gary J
GJ
D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000302:isolation & purification; D057134:Antibodies, Neutralizing / Q000276:immunology* / Q000302:isolation & purification; D001402:B-Lymphocytes / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology* / Q000302:isolation & purification; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008954:Models, Biological
D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015483:HIV Antibodies